Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple filter tame the deadly inflammation of heart shock?

NCT ID NCT04886180

Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether adding an Oxiris membrane—a special blood filter that removes toxins and inflammatory molecules—to the ECMO circuit can reduce the harmful inflammation and organ damage that often occurs when blood flow is restored after cardiogenic shock. The trial enrolls adults with refractory cardiogenic shock who are already on ECMO and need continuous kidney replacement therapy. Participants are randomly assigned to receive either the Oxiris membrane or a standard filter for 24 hours, with blood tests measuring inflammatory markers over several days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxiris membrane (a special filter for blood purification)
What this could lead to
If effective, this approach could reduce inflammation and organ failure in patients on ECMO for cardiogenic shock, potentially improving survival.
What could go wrong
This is a small pilot study with only 40 participants, so results may not be conclusive. The membrane may not significantly improve outcomes or could cause unexpected complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

May 2021

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Trusted person or relative who has given oral consent or emergency consent * Person of legal age * Patient receiving ECLS for refractory cardiogenic shock requiring continuous renal replacement therapy * Included within 12 hours of ECLS initiation Exclusion Criteria: * Person not affiliated to national health insurance * Person under legal protection (curatorship, guardianship) * Person under court order * Pregnant or breastfeeding woman * Minor * Severe hemorrhage under ECLS

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.